MO1 - COMBINING INTERNALLY VALID TRIAL EVIDENCE WITH GENERALIZABLE REAL-WORLD DATA- INSIGHTS INTO EFFECTS, COSTS, AND COST-EFFECTIVENESS OF NOVEL TREATMENT SEQUENCES IN PATIENTS WITH MULTIPLE MYELOMA

Abstract

Authors

H. Blommestein C. van Beurden-Tan S. de Groot N. Blijlevens P. Sonneveld Uyl-de Groot CA S. Zweegman M.G. Franken